By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pluristem Therapeutics 

New York  New York    U.S.A.
Phone: n/a Fax: n/a



Company News
U.S. Department Of Defense To Conduct Studies Of Pluristem Therapeutics (PSTI)’s PLX-R18 In A New ARS Project For Use Before Radiation Exposure 8/16/2017 7:15:18 AM
Israeli Government To Support Pluristem Therapeutics (PSTI)’s Marketing Activity In China – Ministry Of Economy Awards Company "Smart Money" Grant 8/10/2017 12:10:51 PM
Pluristem Therapeutics (PSTI) Release: New Data From ARS Study Shows Significant Hematological Deficiencies Even At Low Radiation Levels; PLX-R18 Supports Hematological Recovery 7/28/2017 8:45:17 AM
Pluristem Therapeutics (PSTI) Advances Its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation At 40 Active Sites By The End Of 2017 7/10/2017 9:18:23 AM
Pluristem Therapeutics (PSTI) Provides Shareholder Update On Corporate And Clinical Developments 5/22/2017 8:17:07 AM
Pluristem Therapeutics (PSTI) Announces Promising Results From Non-Human Primate Pilot Study Of PLX-R18 In Acute Radiation Syndrome 5/3/2017 10:31:42 AM
Pluristem Therapeutics (PSTI) Reaches Milestone Of 100 Granted Patents, Including Coverage Of Leading Indications In Major Markets 4/19/2017 8:41:23 AM
Pluristem Therapeutics (PSTI) Launches Co-CEO Structure And Appoints New CFO 3/30/2017 8:37:18 AM
Pluristem Therapeutics (PSTI) Release: Company Receives Clearance From Germany To Initiate Its Multinational Phase III Trial In Critical Limb Ischemia Targeting Early Conditional Marketing Approval 1/17/2017 12:41:36 PM
Pluristem Therapeutics (PSTI) Release: Company’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA 1/10/2017 11:04:14 AM